Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an announcement.
China Resources Pharmaceutical Group Limited has announced a further delay in sending a shareholder circular related to its sales framework agreement with China Resources Healthcare Group Limited. The company now expects to dispatch the circular, along with accompanying display documents that require additional preparation and finalisation time, on or before 20 January 2026, a slight postponement from the previously indicated mid-January timeline, which may marginally extend the information and decision-making process for shareholders on this related-party transaction.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong-incorporated company listed on the Stock Exchange of Hong Kong, operating in the pharmaceutical sector. The group is part of the wider China Resources conglomerate and is overseen by a board comprising executive, non-executive and independent non-executive directors, reflecting a typical governance structure for a large listed healthcare and pharmaceutical enterprise.
Average Trading Volume: 12,867,200
Technical Sentiment Signal: Sell
Current Market Cap: HK$29.09B
Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.